% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Vraljai:277890,
      author       = {R. Váraljai$^*$ and L. Zimmer$^*$ and Y. Al-Matary$^*$ and
                      P. Kaptein and L. J. Albrecht$^*$ and B. Shannan$^*$ and J.
                      C. Brase and D. Gusenleitner and T. Amaral and N. Wyss and
                      J. Utikal$^*$ and L. Flatz and F. Rambow$^*$ and H. C.
                      Reinhardt and J. Dick and D. R. Engel and S. Horn$^*$ and S.
                      Ugurel$^*$ and W. Sondermann$^*$ and E. Livingstone$^*$ and
                      A. Sucker$^*$ and A. Paschen$^*$ and F. Zhao$^*$ and J. M.
                      Placke$^*$ and J. M. Klose and W. P. Fendler and D. S.
                      Thommen and I. Helfrich$^*$ and D. Schadendorf$^*$ and A.
                      Roesch$^*$},
      title        = {{I}nterleukin 17 signaling supports clinical benefit of
                      dual {CTLA}-4 and {PD}-1 checkpoint inhibition in melanoma.},
      journal      = {Nature cancer},
      volume       = {4},
      number       = {9},
      issn         = {2662-1347},
      address      = {London},
      publisher    = {Nature Research},
      reportid     = {DKFZ-2023-01557},
      pages        = {1292-1308},
      year         = {2023},
      note         = {2023 Sep;4(9):1292-1308},
      abstract     = {Recent studies suggest that BRAFV600-mutated melanomas in
                      particular respond to dual anti-programmed cell death
                      protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated
                      protein 4 (CTLA-4) immune checkpoint inhibition (ICI). Here
                      we identified an over-representation of interleukin
                      (IL)-17-type 17 helper T (TH17) gene expression signatures
                      (GES) in BRAFV600-mutated tumors. Moreover, high baseline
                      IL-17 GES consistently predicted clinical responses in
                      dual-ICI-treated patient cohorts but not in mono anti-CTLA-4
                      or anti-PD-1 ICI cohorts. High IL-17 GES corresponded to
                      tumor infiltration with T cells and neutrophils.
                      Accordingly, high neutrophil infiltration correlated with
                      clinical response specifically to dual ICI, and
                      tumor-associated neutrophils also showed strong IL-17-TH17
                      pathway activity and T cell activation capacity. Both the
                      blockade of IL-17A and the depletion of neutrophils impaired
                      dual-ICI response and decreased T cell activation. Finally,
                      high IL-17A levels in the blood of patients with melanoma
                      indicated a higher global TH17 cytokine profile preceding
                      clinical response to dual ICI but not to anti-PD-1
                      monotherapy, suggesting a future role as a biomarker for
                      patient stratification.},
      cin          = {ED01 / A370},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331 / I:(DE-He78)A370-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37525015},
      doi          = {10.1038/s43018-023-00610-2},
      url          = {https://inrepo02.dkfz.de/record/277890},
}